Apyx Medical Corporation
5115 Ulmerton Road
Clearwater
FL
33760
United States
Tel: 1-800-537-2790
Website: http://www.apyxmedical.com/
231 articles about Apyx Medical Corporation
-
Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit
4/11/2024
Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit.
-
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook
3/21/2024
Apyx Medical Corporation today reported financial results for its fourth quarter and full year ended December 31, 2023.
-
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024
3/4/2024
Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st.
-
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results
1/8/2024
Apyx Medical Corporation, the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, reported preliminary revenue results for the fourth quarter and full year ended December 31, 2023.
-
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
11/28/2023
Apyx Medical Corporation today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023.
-
Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors
11/9/2023
Apyx Medical Corporation today announced that the Company and its subsidiaries have entered into a new, five-year credit agreement with Perceptive Credit Holdings IV, LP (“Perceptive”), an affiliate of Perceptive Advisors.
-
Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
11/9/2023
Apyx Medical Corporation reported financial results for its third quarter ended September 30, 2023, and updated its financial expectations for the full year ending December 31, 2023.
-
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
10/2/2023
Apyx ® Medical Corporation today announced that financial results for the third quarter of fiscal year 2023 will be released before the market opens on Thursday, November 9th.
-
Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook
8/10/2023
Apyx Medical Corporation, the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, reported financial results for its second quarter ended June 30, 2023, and reaffirms financial expectations for the full year ending December 31, 2023.
-
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2023 Financial Results on August 10, 2023
6/29/2023
Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”) today announced that financial results for the second quarter of fiscal year 2023 will be released after the market closes on Thursday, August 10th.
-
Apyx Medical Corporation Announces FDA 510(k) Clearance for the Renuvion® Micro Handpiece
6/14/2023
Apyx Medical Corporation announced it has received 510 clearance from the U.S. Food and Drug Administration for the Renuvion Micro Handpiece, a new addition to the Renuvion product family.
-
Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
5/11/2023
Apyx Medical Corporation today reported financial results for its first quarter ended March 31, 2023, and updated financial expectations for the full year ending December 31, 2023.
-
RENUVION® RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTION
5/2/2023
Apyx Medical Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for the use of its APR Handpiece in procedures for coagulation of soft tissues following liposuction, the most popular plastic surgery procedure in the world.
-
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring
4/28/2023
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion ® for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring.
-
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
4/5/2023
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2023 will be released before the market opens on Thursday, May 11th.
-
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook
3/16/2023
Apyx Medical Corporation today reported financial results for its fourth quarter and full year ended December 31, 2022, and introduced financial expectations for the full year ending December 31, 2023.
-
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissue, Where Needed
2/27/2023
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion ® to Coagulate and Contract Soft Tissues.
-
Apyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial
2/21/2023
Apyx Medical Corporation today announced that the Company and its subsidiaries have entered into a new, five-year secured credit facility with MidCap Financial.
-
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2022 Financial Results on March 16, 2023
2/16/2023
Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2022 will be released before the market opens on Thursday, March 16th.
-
Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of the Renuvion® APR Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction
2/1/2023
Apyx Medical Corporation today announced it has submitted a 510(k) premarket notification (“510(k) submission”) for Renuvion APR Handpiece to the U.S. Food and Drug Administration (“FDA”), supported by a clinical study and real-world evidence.